Moderators: Jubilee Brown, MD and R. Tyler Hillman, MD

Presentations:

• Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low grade serous ovarian cancer ( Blair C. McNamara, MD)
• Efficacy of Sintilimab (Sin) + Bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial ( Qinglei Gao, MD)
• Capitalizing on absence of TP53 mutations in low-grade serous and clear cell ovarian cancer with XPO1 inhibition ( Dimitrios Nasioudis, MD)
• TP53 and KRAS somatic mutations are associated with worse outcomes in stage I mucinous ovarian carcinomas ( Yingao Zhang, MD)
• Distillation: Translational Science in Rare Ovarian Tumors ( Mark Carey, MD, FRCSC)
• Gamma Secretase Inhibitors in Combination with Cytotoxic Agents Decrease Migration and Invasion Uterine Leiomyosarcoma ( Yasmin Abedin, MD)
• Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT ( Thomas J. Herzog, MD)
• Compare the outcomes between open and minimally invasive surgery (MIS) surgery procedures in Primary malignant melanoma of the vagina and cervix (Cuibo Lin, MD)
• Distillation: Designing the Future of Rare Tumor Trials ( Isabelle Ray-Coquard, MD, PhD)